Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer

Conclusions: Biosimilar trastuzumab demonstrated similar safety and effectiveness to Herceptin. The findings can help improve confidence in and use of biosimilars and demonstrate the value of real-world evidence generation for supporting biosimilar implementations and reassessments.PMID:38534957 | PMC:PMC10969053 | DOI:10.3390/curroncol31030124

Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Caroline Mu ñoz Xiaochen Tai Jessica Arias Andrea Eisen Munaza Chaudhry Scott Gavura Kelvin K W Chan Source Type: research